JP2004196750A - Stress reliever - Google Patents

Stress reliever Download PDF

Info

Publication number
JP2004196750A
JP2004196750A JP2002370604A JP2002370604A JP2004196750A JP 2004196750 A JP2004196750 A JP 2004196750A JP 2002370604 A JP2002370604 A JP 2002370604A JP 2002370604 A JP2002370604 A JP 2002370604A JP 2004196750 A JP2004196750 A JP 2004196750A
Authority
JP
Japan
Prior art keywords
extract
black cohosh
stress
water
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002370604A
Other languages
Japanese (ja)
Other versions
JP4605984B2 (en
Inventor
Isao Nadaoka
勲 灘岡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Breweries Ltd
Original Assignee
Asahi Breweries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Breweries Ltd filed Critical Asahi Breweries Ltd
Priority to JP2002370604A priority Critical patent/JP4605984B2/en
Publication of JP2004196750A publication Critical patent/JP2004196750A/en
Application granted granted Critical
Publication of JP4605984B2 publication Critical patent/JP4605984B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a stress reliever containing an extract of black cohosh (Cimicifuga racemosa) as an active ingredient and to provide a food, a functional food, a beverage and a medicine each containing the stress reliever. <P>SOLUTION: The stress reliever comprises the extract of black cohosh as the active ingredient. In the stress reliever, black cohosh itself or its extract can be used. The black cohosh extract is obtained by extracting the black cohosh with water, ethanol or water-containing ethanol or other organic solvent and concentrating the extracted solution or purifying the resultant extract by using an ultrafiltration membrane. Although the leaf, stem, flower, rhizome, etc., of black cohosh can be used for extraction, the rhizome can preferably be used. There is further provided a composition containing the black cohosh extract and having stress-relieving action and the composition has preferably a form of food, dietary supplement, functional food or medicine. <P>COPYRIGHT: (C)2004,JPO&NCIPI

Description

【0001】
【発明の属する技術分野】
ブラックコホシュまたはその抽出物を有効成分とするストレス緩和剤に関する。
【0002】
【従来の技術】
現代はストレス過負荷の時代であり、現代に暮らすものは多かれ少なかれ、負荷されたストレスの影響のもとに暮らしている。このようなストレスの人体に及ぼす影響は近年になって詳細に調査されるようになり、予想外に大きな影響を及ぼすことが明確になりつつある。近年社会的に衝撃を与えるような犯罪事件が多いのも、このようなストレスの影響によるものだといわれている。ストレスの原因を減らすことが根本的な解決手段であるが、それが困難なのが現状であり、ストレスの影響を緩和させるような食品素材が望まれている。
【0003】
ストレスの影響からの回復やストレスによる鬱状態の改善が期待される植物抽出物、漢方生薬抽出物が知られている。たとえば、マメ科コンメイケットウ、カンラン科モツヤクジュ、ユリ科アロエ、オミナエシ科カンショウコウ、セリ科サンゴナ、ヤドリギ科ソウキセイ、マオウ科シナマオウ、ショウガ科ショウガ、マメ科クズ、キンポウゲ科オキナグサ、ミカン科ハクセン、セリ科キョウカツの漢方生薬の基源植物のエッセンスからなるストレスの悪影響からの回復促進剤(例えば、特許文献1参照)や、羅布麻抽出物を含有する抗鬱作用を有する食品、栄養補助食品、医薬品(例えば、特許文献2参照)がある。
【0004】
また、ブラックコホシュは、シミシフガ・ラセモサ(Cimicifuga racemosa)の学名で、キンポウゲ科に属する植物である。その主成分のシミシフギン(Cimicifugin)は急激なエストロゲンの減少を抑えて、更年期障害の症状を和らげることが知られている。ブラックコホシュ抽出物の使用については、心臓血管疾患、特にアテローム性動脈硬化症、骨粗鬆症及び更年期障害の治療及び/又は予防、例えば一過性熱感の予防又は軽減のためのエストロゲン型期間選択性薬剤として開示されている(特許文献3)。しかし、ストレス緩和作用は言及されていない。
【0005】
【特許文献1】特開2001−192338号公報
【特許文献2】特開2002−201139号公報
【特許文献3】特表2002−506827号公報
【0006】
【発明が解決しようとする課題】
本発明の目的は、天然由来で、しかも長期服用しても安全なストレス緩和剤を提供することである。
【0007】
【課題を解決するための手段】
本発明者らは、鋭意検討した結果、ブラックコホシュ抽出物がストレス緩和作用を示すことを見出し、本発明を完成するに至った。
【0008】
したがって、本発明はブラックコホシュ抽出物を有効成分とするストレス緩和剤を提供することである。さらに、上記ストレス緩和剤を含有する食品、機能性食品、飲料、医薬品を提供する。
【0009】
【発明の実施の形態】
本発明におけるストレス緩和剤にはブラックコホシュそのものもしくはその抽出物を用いることができる。ブラックコホシュ抽出物としては、ブラックコホシュを水あるいはエタノールまたは含水エタノールあるいは有機溶剤で抽出、濃縮して得られる抽出物、およびここで得られる抽出物を限外濾過膜を用いて精製して得られるものである。ブラックコホシュの葉、茎、花、根茎等を抽出に用いることができるが、根茎が好ましい。含水エタノールとしてはエタノール濃度10〜95%で、30〜70%が好ましく、さらに50%が好ましい。
【0010】
本発明はさらに、ブラックコホシュ抽出物を含むストレス緩和作用を有する組成物を提供し、この組成物は好ましくは食品、栄養補助食品、機能性食品または医薬品の形態である。本発明の組成物が医薬用組成物であるときの投与方法は特に限定されるものではないが、経口投与可能な剤形が好ましい。本発明の医薬用組成物は種々の剤形とすることができる。例えば、経口投与のためには、錠剤、カプセル剤、散剤、顆粒剤、丸剤、液剤、乳剤、トローチ剤、懸濁剤、溶液剤、酒精剤、シロップ剤、抽出物剤、エリキシル剤とすることができるが、これらに限定されない。また、製剤には薬剤的に許容できる種々の担体を加えることができる。例えば、賦形剤、結合剤、崩壊剤、滑沢剤、着香剤、着色剤、甘味剤、矯味剤、溶解補助剤、懸濁化剤、乳化剤、コーティング剤、ビタミンC、抗酸化剤を含むことができるが、これらに限定されない。
【0011】
本発明の医薬用組成物の投与量は、一般的には、ブラックコホシュ抽出物に換算して成人1日用量として1mg〜2000mg、好ましくは1mg〜1000mgを使用する。もちろん個別的に、投与されるヒトの年齢、体重、症状、投与経路、投与期間、治療経過等に応じて変化させることもできる。1日あたりの量を数回に分けて投与することもできる。また、他のストレス緩和剤や治療法と組み合わせて投与することもできる。
【0012】
本発明の組成物は、食品又は栄養補助食品の形態とすることもできる。例えば、ブラックコホシュ抽出物を原材料に配合することにより、麺類、パン、キャンディー、ゼリー、クッキー、スープ、健康飲料の形態とすることができる。このような食品、栄養補助食品、機能性食品にはブラックコホシュ抽出物の他に、鉄、カルシウム等の無機成分、種々のビタミン類、オリゴ糖、キトサン等の食物繊維、大豆抽出物等のタンパク質、レシチンなどの脂質、ショ糖、乳糖等の糖類を加えることができる。
【0013】
また、本発明のブラックコホシュ抽出物に羅布麻抽出物、高麗ニンジン抽出物、イチョウ葉抽出物、ツボクサ抽出物、エゾウコギ抽出物、オウギ抽出物、ガラナ抽出物、マカ抽出物、タンポポ抽出物、アーティチョーク抽出物、ゲンチアナ抽出物、シサンドラ抽出物、西洋カボチャ抽出物、大豆抽出物、甘草抽出物、当帰抽出物、西洋ニンジンボク抽出物、ザクロ抽出物、ヤムイモ抽出物、オオアワダチソウ抽出物、キダチアロエ抽出物、田七ニンジン抽出物、チャボトケイソウ抽出物、ヤドリギ抽出物などを組み合わせることにより、精神的ストレスから陥る症状の緩和効果を有する食品、栄養補助食品、機能性食品、医薬品などの組成物が得られる。
【0014】
【発明の効果】
本発明のブラックコホシュ抽出物はストレス緩和作用を示し、ストレス緩和剤の成分として有用である。また、ブラックコホシュ抽出物はストレス緩和を目的とした食品、栄養補助食品、機能性食品、医薬品などの組成物に利用できる。
【0015】
【実施例】
実施例1 ブラックコホシュ抽出物の精製
ブラックコホシュの根茎 5.2kgを50%含水エタノール10リットルで抽出し濃縮した後、乾燥し445gの抽出物を得た。
【0016】
実施例2 ストレス緩和作用の検討
6週齢のBALB/c雄性マウスを用いて検討した。1週間予備飼育後、7週齢の時点で実施例1で得たブラックコホシュ抽出物1.0g/kgまたは0.5g/kgまたは0.2g/kgを経口投与した。投与30分後よりマウスを30mlの注射用シリンジ内に閉じ込めるストレスを1時間負荷し、直後に採血を行い血漿中のコルチコステロン濃度、GOT濃度、LDH濃度、IL−6濃度を測定した。
表1に示す通り試験群は対照群に比較して、有意に各パラメータの上昇を用量依存的に抑制した。
【0017】
表1 ブラックコホシュのストレス緩和効果に対する用量依存性
コルチコステロン(ng/ml) GOT(karmen) LDH(IU/l) IL-6(pg/ml)
対照群 559.5±49.0 46.8±3.4 921.7±44.7 7.1±0.6
1.0g/kg群 354.6±20.6** 19.5±1.0** 339.4±24.2** 4.8±0.3**
0.5g/kg群 335.2±28.7** 26.6±1.5** 558.2±63.2** 4.6±0.3**
0.2g/kg群 376.9±40.4** 28.7±3.9** 462.4±68.8** 5.2±0.4*
(n=5, 平均値±標準偏差、 **p<0.01、 *p<0.05)
【0018】
実施例3 雌性マウスによる効果検討
6週齢のBALB/c雌性マウスを用いて検討した。1週間予備飼育後、7週齢の時点で実施例1で得たブラックコホシュ抽出物1.0g/kgを経口投与した。投与30分後よりマウスを30mlの注射用シリンジ内に閉じ込めるストレスを1時間負荷し、直後に採血を行い血漿中のコルチコステロン濃度、GOT濃度、LDH濃度を測定した。
表2に示す通り雄性と同様に試験群は対照群と比較して、有意に各パラメータの上昇を抑制した。
【0019】
表2 ブラックコホシュの雌性に対するストレス緩和効果
コルチコステロン(ng/ml) GOT(karmen) LDH(IU/l)
対照群 719.1±53.9 44.1±5.0 805.2±121.1
1.0g/kg群 480.5±19.5** 22.0±2.1** 303.6±27.2**
(n=5, 平均値±標準偏差、 **p<0.01)
【0020】
実施例4 有効成分抽出法の検討
実施例1で得たブラックコホシュ抽出物(30g)を水溶性画分(1g)と非水溶性画分(29g)に分画し、前述同様に確認試験を行った。その結果非水溶性画分に強い活性が確認された。(表3)
【0021】
表3 ブラックコホシュの有効成分抽出法の検討
コルチコステロン(ng/ml) GOT(karmen) LDH(IU/l)
対照群 600.8±61.1 43.5±5.6 1314.9±198.3
水溶性画分群 525.8±99.8 26.3±2.8* 706.7±116.4*
非水溶性画分群 462.7±39.1 19.4±0.4** 499.8±16.6**
(n=5, 平均値±標準偏差、 **p<0.01、*p<0.05)
以下の実施例では、この実施例で得たブラックコホシュ抽出物の非水溶性画分群を用いた。
【0022】
実施例5(トローチ剤)
アラビアゴム 6.0
ステアリン酸マグネシウム 3.0
ブドウ糖 73.0
乳糖 17.6
リン酸第2カリウム 0.2
リン酸第1カリウム 0.1
香料 0.095
実施例4で得た非水溶性画分群 0.005
合計 100.0
上記の各重量部の各成分を用い、常法に従ってトローチ剤とした。
【0023】
実施例6(飴)
ショ糖 20.0
水飴(75%固形分) 70.0
水 9.5
着色料 0.45
香料 0.045
実施例4で得た非水溶性画分群 0.005
合計 100.0
上記の各重量部の各成分を用い、常法に従って飴とした。
【0024】
実施例7 (チューインガム)
ガムベース 20.0
炭酸カルシウム 2.0
乳糖 77.0
ステビオサイド 0.095
実施例4で得た非水溶性画分群 0.005
香料 0.9
合計 100.0
上記の各重量部の各成分を用い、常法に従ってチューインガムとした。
【0025】
実施例8 (ジュース)
濃縮ミカン果汁 15.0
果糖 5.0
クエン酸 0.2
香料 0.1
色素 0.15
アスコルビン酸ナトリウム 0.048
実施例4で得た非水溶性画分群 0.002
水 79.5
合計 100.0
上記の各重量部の各成分を用い、常法に従ってジュースとした。
【0026】
実施例9 (クッキー)
薄力粉 32.0
全卵 16.0
バター 16.0
砂糖 25.0
水 10.8
ベーキングパウダー 0.198
実施例4で得た非水溶性画分群 0.002
合計 100.0
上記の各重量部の各成分を用い、常法に従ってクッキーとした。
【0027】
実施例10 (キャラメル)
グラニュー糖 31.0
水飴(75%固形分) 20.0
粉乳 40.0
硬化油 5.0
食塩 0.6
香料 0.025
実施例4で得た非水溶性画分群 0.005
水 3.37
合計 100.0
上記の各重量部の各成分を用い、常法に従ってキャラメルとした。
【0028】
実施例11(錠剤、カプセル剤)
実施例4で得た非水溶性画分群 10.0
乳糖 75.0
ステアリン酸マグネシウム 15.0
合計 100.0
上記の各重量部を均一に混合し、常法に従って錠剤、カプセル剤とした。
【0029】
実施例12 (散剤、顆粒剤)
実施例4で得た非水溶性画分群 20.0
澱粉 30.0
乳糖 50.0
合計 100.0
上記の各重量部を均一に混合し、常法に散剤、顆粒剤とした。
【0030】
実施例13 (注射剤)
実施例4で得た非水溶性画分群 1.0
界面活性剤 9.0
生理食塩水 90.0
合計 100.0
上記の各重量部を加熱混合、滅菌して注射剤とした。
[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a stress relieving agent containing black cohosh or an extract thereof as an active ingredient.
[0002]
[Prior art]
Modern times are a time of stress overload, and more or less live today, under the influence of stress. In recent years, the effects of such stress on the human body have been investigated in detail, and it is becoming clear that unexpectedly large effects are exerted. It is said that many criminal cases that have a shocking impact on society in recent years are caused by such stress. Reducing the cause of stress is a fundamental solution, but at present it is difficult, and there is a demand for a food material that reduces the effects of stress.
[0003]
BACKGROUND ART A plant extract and a Chinese herbal extract that are expected to recover from the effects of stress and improve depression due to stress are known. For example, Leguminosae magnolia, Citrus spruce, Lily family aloe, Oleum spp. An agent for promoting recovery from the adverse effects of stress consisting of the essence of the herbal crude drug of the family Kyoukatsu (see, for example, Patent Literature 1), an anti-depressant food containing Lufu hemp extract, a dietary supplement, and a pharmaceutical (For example, see Patent Document 2).
[0004]
Black cohosh is a plant belonging to the family Ranunculaceae under the scientific name of Cimicifuga racemosa. It is known that its main component, Cimicifugin, suppresses a rapid decrease in estrogen and relieves the symptoms of menopause. For the use of black cohosh extract, as an estrogen-type time-selective drug for the treatment and / or prevention of cardiovascular diseases, in particular atherosclerosis, osteoporosis and menopause, for example to prevent or reduce hot flashes. It is disclosed (Patent Document 3). However, no stress relief effect is mentioned.
[0005]
[Patent Document 1] Japanese Patent Application Laid-Open No. 2001-192338 [Patent Document 2] Japanese Patent Application Laid-Open No. 2002-201139 [Patent Document 3] Japanese Patent Application Laid-Open No. 2002-506727
[Problems to be solved by the invention]
An object of the present invention is to provide a stress relieving agent which is naturally derived and safe even when taken for a long time.
[0007]
[Means for Solving the Problems]
Means for Solving the Problems As a result of intensive studies, the present inventors have found that a black cohosh extract exhibits a stress relieving effect, and have completed the present invention.
[0008]
Accordingly, an object of the present invention is to provide a stress relieving agent containing a black cohosh extract as an active ingredient. Further, the present invention provides a food, a functional food, a beverage, and a medicine containing the stress relieving agent.
[0009]
BEST MODE FOR CARRYING OUT THE INVENTION
As the stress relieving agent in the present invention, black cohosh itself or an extract thereof can be used. The black cohosh extract is an extract obtained by extracting and concentrating black cohosh with water or ethanol or aqueous ethanol or an organic solvent, and an extract obtained by purifying the extract obtained here using an ultrafiltration membrane. is there. Black cohosh leaves, stems, flowers, rhizomes and the like can be used for extraction, but rhizomes are preferred. The hydrated ethanol has an ethanol concentration of 10 to 95%, preferably 30 to 70%, and more preferably 50%.
[0010]
The present invention further provides a composition having a stress-relieving action comprising a black cohosh extract, which composition is preferably in the form of a food, dietary supplement, functional food or pharmaceutical product. The method of administration when the composition of the present invention is a pharmaceutical composition is not particularly limited, but a dosage form capable of oral administration is preferred. The pharmaceutical composition of the present invention can be in various dosage forms. For example, for oral administration, tablets, capsules, powders, granules, pills, solutions, emulsions, troches, suspensions, solutions, alcoholic beverages, syrups, extracts, elixirs But not limited to these. In addition, various pharmaceutically acceptable carriers can be added to the preparation. For example, excipients, binders, disintegrants, lubricants, flavoring agents, coloring agents, sweeteners, flavoring agents, solubilizing agents, suspending agents, emulsifiers, coating agents, vitamin C, antioxidants But may be, but not limited to.
[0011]
The dose of the pharmaceutical composition of the present invention is generally 1 mg to 2000 mg, preferably 1 mg to 1000 mg, as a daily dose for an adult in terms of black cohosh extract. Of course, it can also be varied individually depending on the age, weight, condition, administration route, administration period, treatment course, etc. of the human being administered. The daily dose can be administered in several divided doses. It can also be administered in combination with other stress relievers and treatments.
[0012]
The compositions of the present invention can also be in the form of a food or dietary supplement. For example, by blending the black cohosh extract with the raw material, it can be made into the form of noodles, bread, candy, jelly, cookies, soup, and health drink. Such foods, dietary supplements, functional foods other than black cohosh extract, iron, inorganic components such as calcium, various vitamins, oligosaccharides, dietary fiber such as chitosan, protein such as soy extract, Lipids such as lecithin and sugars such as sucrose and lactose can be added.
[0013]
In addition, the black cohosh extract of the present invention contains Rafu hemp extract, Korean ginseng extract, Ginkgo biloba extract, Tubulus extract, Eleuthero extract, Forage extract, Guarana extract, Maca extract, Dandelion extract, Artichoke extract , Gentian extract, sisandra extract, western squash extract, soybean extract, licorice extract, toki extract, western carrot extract, pomegranate extract, yam extract, oak radishes extract, kidachi aloe extract, The combination of the extract of ginseng ginseng, the extract of radishes, the extract of mistletoe, and the like can provide compositions such as foods, dietary supplements, functional foods, and pharmaceuticals that have the effect of alleviating the symptoms of mental stress.
[0014]
【The invention's effect】
The black cohosh extract of the present invention exhibits a stress relieving effect and is useful as a component of a stress relieving agent. In addition, the black cohosh extract can be used in compositions such as foods for reducing stress, dietary supplements, functional foods, and pharmaceuticals.
[0015]
【Example】
Example 1 Purification of black cohosh extract 5.2 kg of rhizome of black cohosh was extracted with 10 liters of 50% aqueous ethanol, concentrated, and then dried to obtain 445 g of an extract.
[0016]
Example 2 Examination of Stress Relief Action The study was performed using 6-week-old BALB / c male mice. After pre-breeding for 1 week, at the age of 7 weeks, 1.0 g / kg, 0.5 g / kg, or 0.2 g / kg of the black cohosh extract obtained in Example 1 was orally administered. Thirty minutes after the administration, the mice were loaded with a stress for confining them in a 30 ml syringe for injection for one hour, and blood was immediately collected to measure the corticosterone concentration, the GOT concentration, the LDH concentration, and the IL-6 concentration in the plasma.
As shown in Table 1, the test group significantly suppressed the increase of each parameter in a dose-dependent manner as compared with the control group.
[0017]
Table 1 Dose-dependent corticosterone (ng / ml) on stress relief effect of black cohosh GOT (karmen) LDH (IU / l) IL-6 (pg / ml)
Control group 559.5 ± 49.0 46.8 ± 3.4 921.7 ± 44.7 7.1 ± 0.6
1.0g / kg group 354.6 ± 20.6 ** 19.5 ± 1.0 ** 339.4 ± 24.2 ** 4.8 ± 0.3 **
0.5g / kg group 335.2 ± 28.7 ** 26.6 ± 1.5 ** 558.2 ± 63.2 ** 4.6 ± 0.3 **
0.2g / kg group 376.9 ± 40.4 ** 28.7 ± 3.9 ** 462.4 ± 68.8 ** 5.2 ± 0.4 *
(N = 5, mean ± standard deviation, ** p <0.01, * p <0.05)
[0018]
Example 3 Examination of effect with female mice The study was conducted using 6-week-old BALB / c female mice. After pre-breeding for one week, at the age of seven weeks, 1.0 g / kg of the black cohosh extract obtained in Example 1 was orally administered. Thirty minutes after the administration, a stress for confining the mouse in a 30 ml syringe for injection was applied for 1 hour, and blood was immediately collected to measure corticosterone concentration, GOT concentration, and LDH concentration in plasma.
As shown in Table 2, similarly to the male group, the test group significantly suppressed the increase of each parameter as compared with the control group.
[0019]
Table 2 Stress relief effect of black cohosh on female sex corticosterone (ng / ml) GOT (karmen) LDH (IU / l)
Control group 719.1 ± 53.9 44.1 ± 5.0 805.2 ± 121.1
1.0g / kg group 480.5 ± 19.5 ** 22.0 ± 2.1 ** 303.6 ± 27.2 **
(N = 5, mean ± standard deviation, ** p <0.01)
[0020]
Example 4 Examination of Active Ingredient Extraction Method The black cohosh extract (30 g) obtained in Example 1 was fractionated into a water-soluble fraction (1 g) and a water-insoluble fraction (29 g), and a confirmation test was carried out in the same manner as described above. Was. As a result, a strong activity was confirmed in the water-insoluble fraction. (Table 3)
[0021]
Table 3 Examination of active ingredient extraction method of black cohosh Corticosterone (ng / ml) GOT (karmen) LDH (IU / l)
Control group 600.8 ± 61.1 43.5 ± 5.6 1314.9 ± 198.3
Water-soluble fraction group 525.8 ± 99.8 26.3 ± 2.8 * 706.7 ± 116.4 *
Water-insoluble fraction group 462.7 ± 39.1 19.4 ± 0.4 ** 499.8 ± 16.6 **
(N = 5, mean ± standard deviation, ** p <0.01, * p <0.05)
In the following examples, a group of water-insoluble fractions of the black cohosh extract obtained in this example was used.
[0022]
Example 5 (troche)
Gum arabic 6.0
Magnesium stearate 3.0
Glucose 73.0
Lactose 17.6
Potassium phosphate 0.2
Potassium phosphate 0.1
Fragrance 0.095
Water-insoluble fraction group obtained in Example 4 0.005
Total 100.0
A lozenge was prepared according to a conventional method using each of the above parts by weight.
[0023]
Example 6 (candy)
Sucrose 20.0
Candy syrup (75% solids) 70.0
Water 9.5
Coloring agent 0.45
Fragrance 0.045
Water-insoluble fraction group obtained in Example 4 0.005
Total 100.0
A candy was prepared according to a conventional method using the above components in each part by weight.
[0024]
Example 7 (chewing gum)
Gum base 20.0
Calcium carbonate 2.0
Lactose 77.0
Stevioside 0.095
Water-insoluble fraction group obtained in Example 4 0.005
Fragrance 0.9
Total 100.0
Chewing gum was prepared according to a conventional method using the above components in each part by weight.
[0025]
Example 8 (juice)
Concentrated orange juice 15.0
Fructose 5.0
Citric acid 0.2
Fragrance 0.1
Pigment 0.15
Sodium ascorbate 0.048
Water-insoluble fraction group obtained in Example 4 0.002
79.5 water
Total 100.0
A juice was prepared using the above-mentioned respective parts by weight and in accordance with a conventional method.
[0026]
Example 9 (Cookie)
Soft flour 32.0
Whole egg 16.0
Butter 16.0
Sugar 25.0
Water 10.8
Baking powder 0.198
Water-insoluble fraction group obtained in Example 4 0.002
Total 100.0
A cookie was prepared according to a conventional method using the above components in each part by weight.
[0027]
Example 10 (caramel)
Granulated sugar 31.0
Candy syrup (75% solids) 20.0
Powdered milk 40.0
Hardened oil 5.0
Salt 0.6
Fragrance 0.025
Water-insoluble fraction group obtained in Example 4 0.005
Water 3.37
Total 100.0
Using the above-mentioned respective parts by weight of each component, caramel was prepared according to a conventional method.
[0028]
Example 11 (tablets, capsules)
Water-insoluble fraction group obtained in Example 4 10.0
Lactose 75.0
Magnesium stearate 15.0
Total 100.0
The above parts by weight were uniformly mixed to obtain tablets and capsules according to a conventional method.
[0029]
Example 12 (powder, granule)
The water-insoluble fraction group obtained in Example 4 20.0
Starch 30.0
Lactose 50.0
Total 100.0
The above parts by weight were uniformly mixed to give powders and granules in a conventional manner.
[0030]
Example 13 (injection)
The water-insoluble fraction group obtained in Example 4 1.0
Surfactant 9.0
Physiological saline 90.0
Total 100.0
Each of the above parts by weight was heated, mixed and sterilized to give an injection.

Claims (4)

ブラックコホシュを有効成分とするストレス緩和剤。A stress relieving agent containing black cohosh as an active ingredient. ブラックコホシュ抽出物を有効成分とするストレス緩和剤。A stress relieving agent containing a black cohosh extract as an active ingredient. ブラックコホシュまたはその抽出物を含有するストレス緩和作用を有する組成物。A composition having a stress relieving effect, comprising black cohosh or an extract thereof. 組成物が食品、栄養補助食品、機能性食品または医薬品である請求項3の組成物。4. The composition according to claim 3, wherein the composition is a food, a dietary supplement, a functional food or a pharmaceutical.
JP2002370604A 2002-12-20 2002-12-20 Stress relieving agent Expired - Fee Related JP4605984B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002370604A JP4605984B2 (en) 2002-12-20 2002-12-20 Stress relieving agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002370604A JP4605984B2 (en) 2002-12-20 2002-12-20 Stress relieving agent

Publications (2)

Publication Number Publication Date
JP2004196750A true JP2004196750A (en) 2004-07-15
JP4605984B2 JP4605984B2 (en) 2011-01-05

Family

ID=32766477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002370604A Expired - Fee Related JP4605984B2 (en) 2002-12-20 2002-12-20 Stress relieving agent

Country Status (1)

Country Link
JP (1) JP4605984B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007008817A (en) * 2005-06-28 2007-01-18 Ezaki Glico Co Ltd TNF-alpha AND NITRIC OXIDE PRODUCTION INHIBITOR
KR20180005997A (en) * 2016-07-07 2018-01-17 주식회사 네이처센스 농업회사법인 Composition for preventing or alleviating stress-involved disease
KR20180019629A (en) * 2018-02-13 2018-02-26 주식회사 네이처센스 농업회사법인 Composition for preventing or alleviating stress-involved disease
WO2021011790A1 (en) * 2019-07-16 2021-01-21 Advanced Female Technologies Llc Chewing gum compositions for the treatment of menstrual pain

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506827A (en) * 1998-03-19 2002-03-05 ビオノリカ アクチェンゲゼルシャフト Use of extracts of Iridaceae and Cimicifugaracemosa and tectrigenin as estrogen-type organ-selective drugs without uterotropic action

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506827A (en) * 1998-03-19 2002-03-05 ビオノリカ アクチェンゲゼルシャフト Use of extracts of Iridaceae and Cimicifugaracemosa and tectrigenin as estrogen-type organ-selective drugs without uterotropic action

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007008817A (en) * 2005-06-28 2007-01-18 Ezaki Glico Co Ltd TNF-alpha AND NITRIC OXIDE PRODUCTION INHIBITOR
KR20180005997A (en) * 2016-07-07 2018-01-17 주식회사 네이처센스 농업회사법인 Composition for preventing or alleviating stress-involved disease
KR102020644B1 (en) * 2016-07-07 2019-09-10 주식회사 네이처센스 농업회사법인 Composition for preventing or alleviating stress-involved disease
KR20180019629A (en) * 2018-02-13 2018-02-26 주식회사 네이처센스 농업회사법인 Composition for preventing or alleviating stress-involved disease
KR102020642B1 (en) 2018-02-13 2019-09-10 주식회사 네이처센스 농업회사법인 Composition for preventing or alleviating stress-involved disease
WO2021011790A1 (en) * 2019-07-16 2021-01-21 Advanced Female Technologies Llc Chewing gum compositions for the treatment of menstrual pain

Also Published As

Publication number Publication date
JP4605984B2 (en) 2011-01-05

Similar Documents

Publication Publication Date Title
EP2224939B1 (en) Preparations with rosehip extracts, and method of producing rosehip extracts
KR20030059984A (en) A new process for enhancing the efficacies of Ginseng and the uses of the Ginseng extract
Naeem et al. Advancement and future directions towards herbal treatment for various diseases
JP5275251B2 (en) Composition comprising an extract of a combined herb for preventing and treating liver disease
CN114502184A (en) Pharmaceutical and food compositions for the prevention and treatment of coronavirus infection comprising Elaeagnus dulcis extract
US7514104B2 (en) Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory
Moreira et al. The neuroprotective effect of traditional Chinese medicinal plants—A critical review
JP2006083151A (en) Composition for preventing and ameliorating osteoporosis
WO2016190566A9 (en) Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient
WO2005105125A1 (en) Preventive or remedy for osteroporosis
MXPA06007498A (en) Composition comprising an aqueous extract of red vine leaves and a blood circulation-improving agent for the treatment of chronic venous insufficiences.
KR101043212B1 (en) A food for improving brain function
KR101228920B1 (en) A composition comprising of a leaf extract of dendropanax morbifera for treating and preventing intestinal function disorder
EP1889638A1 (en) Medicaments and food for treatment or prevention of obesity and/or diabetes containing cicer arietinum extract
KR100522579B1 (en) Pharmaceutical composition comprising the extracts of scutellaria root and schizandra fruit mixture thereof having an effect of restraint stress
US8895083B2 (en) Composition for the maintenance of blood sugar levels comprising cinnamon and ginseng
MXPA06007497A (en) Composition comprising an aqueous extract of red vine leaves and a antithrombotic agent for the treatment of chronic venous insufficiences.
JP4605984B2 (en) Stress relieving agent
JP2018506524A (en) Composition for prevention, amelioration or treatment of burnout syndrome
JPH06183985A (en) Preventive and therapeutic agent for bone resorption disease
KR101842786B1 (en) A composition for treating atopic dermatitis comprising the extract of herbal mixture
JP4210190B2 (en) Stress relieving agent
KR101248378B1 (en) Pharmaceutical composition for arthritis treatment and prevention
KR101468288B1 (en) Pharmaceutical composition for prevention or treatment of Parkinson&#39;s disease comprising Eucommiae ulmoides extract or fraction thereof
KR20130070616A (en) A composition for prevention and treatment of dementia or parkinson&#39;s disease comprising extracts of morus alba or lycium chinense, or mixture thereof as an active ingredient

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090106

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100223

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100408

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100629

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100722

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100722

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100928

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101005

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131015

Year of fee payment: 3

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131015

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees